Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.

Interventions

  • BIOLOGICAL Pentavalent Meningococcal ABCYW vaccine
  • BIOLOGICAL MenACYW conjugate vaccine
  • BIOLOGICAL Meningococcal group B vaccine

Study Locations (20)

Florida

  • Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400081 — DeLand
  • SIMEDHealth, LLC- Site Number : 8400045 — Gainesville
  • Accel Research Sites-St. Petersburg-Largo- Site Number : 8400082 — Largo
  • South Florida Research Organization Site Number : 8400086 — Medley
  • Life Arc Research-Miami Site Number : 8400094 — Miami
  • Charisma Medical and Research center Site Number : 8400097 — Miami Lakes
  • Accel Research - Nona Pediatric Center Site Number : 8400079 — Orlando
  • Ormond Beach Clinical Research- Site Number : 8400073 — Ormond Beach
  • Palm Harbor Dermatology- Site Number : 8400030 — Tampa
  • PAS Research Site Number : 8400032 — Tampa
  • VICIS Clinical Research-Tampa Site Number : 8400065 — Tampa

California

  • Smart Cures Clinical Research Site Number : 8400072 — Anaheim
  • Hope Clinical Research, LLC- Site Number : 8400001 — Canoga Park
  • Apex Research Group Site Number : 8400071 — Fair Oaks

Alabama

  • Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080 — Birmingham
  • Lakeview Clinical Research Site Number : 8400029 — Guntersville

Arizona

  • Alliance for Multispecialty Research- Phoenix- Site Number : 8400056 — Tempe

Arkansas

  • Harrisburg Family Medical Center Site Number : 8400070 — Harrisburg

District of Columbia

  • Velocity Clinical Research-Washington DC Site Number : 8400102 — Washington D.C.

Idaho

  • Leavitt Clinical Research-Idaho Falls- Site Number : 8400075 — Idaho Falls

Trial Details

FieldValue
Enrollment Target 1,215 participants
Start Date 2023-10-31
Est. Completion 2025-08-27
Phase Phase 1

Sponsor

Sanofi Pasteur, a Sanofi Company

43 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06128733

The ClinicalTrials.gov registry entry for NCT06128733 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 43 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions — of which Pentavalent Meningococcal ABCYW vaccine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06128733 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06128733 about?

NCT06128733 is a clinical study titled "Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents". The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.

What is the current status of trial NCT06128733?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,215 participants. The study started on 2023-10-31. Estimated completion is 2025-08-27.

What conditions does trial NCT06128733 study?

This clinical trial studies the following conditions: Healthy Volunteers, Meningococcal Immunisation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06128733?

The interventions under investigation include: Pentavalent Meningococcal ABCYW vaccine (BIOLOGICAL), MenACYW conjugate vaccine (BIOLOGICAL), Meningococcal group B vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06128733?

This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 43 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06128733 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial